Drug Trial Radar · NCT06946927
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Jun 6, 2025
Primary completion
Feb 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- First posted
- Apr 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
JMKX001899Drug
JMKX001899 tablet administered orally daily.
IN10018Drug
IN10018 tablet administered orally daily.
Chemotherapy: PemetrexedDrug
IV infusion once every 3 weeks
CarboplatinDrug
IV infusion once every 3 weeks, 4 Cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase II dose (RP2D)Time frame: approximately 1 year
- adverse eventsTime frame: Through study completion, approximately 2.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.